| Over a month ago | ||||
Management provides an… Management provides an update on the progress of Portage's adenosine-targeted candidates along with the Company's approach to personalized medicine using biomarkers to identify patients likely to benefit the most from this drug class on a conference call to be held on March 9 at 10:30 am. Webcast Link | ||||
Management provides an… Management provides an update on the progress of Portage's adenosine-targeted candidates along with the Company's approach to personalized medicine using biomarkers to identify patients likely to benefit the most from this drug class on a conference call to be held on March 9 at 10:30 am. Webcast Link | ||||
Management provides an… Management provides an update on the progress of Portage's adenosine-targeted candidates along with the Company's approach to personalized medicine using biomarkers to identify patients likely to benefit the most from this drug class on a conference call to be held on March 9 at 10:30 am. Webcast Link | ||||
"During the quarter… "During the quarter and in recent weeks we continued to progress our clinical programs. Building on the favorable data presented from our lead program - invariant natural killer T cell agonist, PORT-2 - at the 2022 annual meeting of the Society of Immunotherapy of Cancer, we announced a new clinical collaboration agreement with Merck to evaluate PORT-2 in combination with KEYTRUDA (pembrolizumab)," said Dr. Ian Waters, Chief Executive Officer and Chairman of Portage Biotech. "We are expanding this trial internationally and are pleased to announce that our Investigational New Drug application is approved in the U.S., and we are activating U.S. sites. We anticipate establishing the recommended Phase 2 dose shortly and commencing the Phase 2 portion of the IMPORT-201 trial in the second quarter of 2023. | ||||
| Over a quarter ago | ||||
H.C. Wainwright analyst… H.C. Wainwright analyst Robert Burns lowered the firm's price target on Portage Biotech to $21 from $22 and keeps a Buy rating on the shares post the Q2 results. | ||||
Cantor Fitzgerald analyst… Cantor Fitzgerald analyst Li Watsek lowered the firm's price target on Portage Biotech to $18 from $26 and keeps an Overweight rating on the shares. Portage reported Q1 results and maintained its guidance of nine proof-of-concept Phase 1b/2 data updates over the next two years that it believes can drive key value creation, Watsek tells investors in a research note, adding that 2022 is a "foundation year" for Portage. The analyst expects multiple inflection points in 2023. | ||||
Oppenheimer analyst… Oppenheimer analyst Matthew Biegler lowered the firm's price target on Portage Biotech to $18 from $26 on updated risk environment, while keeping an Outperform rating on the shares following Q2 results. The analyst notes Portage has made a sizeable investment in building out what he believes is one of the most extensive portfolios of adenosine receptor antagonists out there. | ||||
As of September 30, the… As of September 30, the company had approximately $15M of cash and cash equivalents, reflecting settlement of the $3M liabilities assumed with the acquisition of the adenosine pipeline. "During the quarter and in recent weeks we have continued to demonstrate progress of our invariant natural killer T cell (iNKT) agonist, PORT-2, as well as our broader portfolio of immuno-oncology assets," said Dr. Ian Waters, Chief Executive Officer and Chairman of Portage Biotech. "Updates on PORT-2 include the data presented from our IMPORT-201 Phase 1/2 clinical trial of PORT-2 (IMM60) at the SITC annual conference, which continue to show PORT-2 has a favorable safety and tolerability profile as a monotherapy at all doses tested to date. We also announced a new clinical collaboration agreement with Merck to evaluate PORT-2 in combination with KEYTRUDA(R) (pembrolizumab), and look forward to exploring how this therapeutic combination may further enhance long-term clinical benefit for a wide range of patients with cancer. We are also preparing to launch our company-sponsored ADPORT-601 adenosine trial for PORT-6 and PORT-7 in the U.S. We look forward to building on this progress and advancing our broader strategy of de-risked clinical development, and are well positioned to deliver on multiple catalysts in the coming months." | ||||
Biotech Analyst Watsek… Biotech Analyst Watsek holds a conference call with CEO Walters and CFO Shaw on November 28 at 2 pm hosted by Cantor Fitzgerald. Webcast Link | ||||
Biotech Analyst Watsek… Biotech Analyst Watsek holds a conference call with CEO Walters and CFO Shaw on November 28 at 2 pm hosted by Cantor Fitzgerald. Webcast Link | ||||
